MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases
December 05 2022 - 2:00AM
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading,
cell-engineering focused company providing enabling platform
technologies to advance the discovery, development and
commercialization of next-generation cell-based therapeutics and to
support innovative, cell-based research, and Curamys, a South
Korean biotechnology company that develops cell & gene therapy
using cell fusion technology to treat rare intractable diseases,
including Duchenne muscular dystrophy and amyotrophic lateral
sclerosis, today announced the signing of a strategic platform
license (SPL).
Under the terms of the agreement, Curamys
obtains non-exclusive clinical and commercial rights to use
MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. In
return, MaxCyte is entitled to receive platform licensing fees and
program-related revenue.
Curamys is focused on developing treatments for
genetic and degenerative diseases through its specialized cell
fusion technology, based on the concept that apoptotic or dying
cells can be regenerated by fusing them with healthy normal
cells. Cell fusion technology can function as a form of gene
therapy when the normal copies of genes existing in treatment cells
are transferred to dying cells, resulting in the development of a
treatments for genetic and rare intractable diseases at the
cellular level.
“A recent report estimates that there are more
than 10,000 distinct rare diseases affecting 400 million people
around the world,” said Doug Doerfler, President and CEO of
MaxCyte. “Many of these diseases, like ALS and DMD, have
few or no treatments. We are honored to support Curamys’ efforts to
develop its cell-fusion technology for novel cell-based treatments
that provide hope and new options to patients and their
families.”
“At Curamys, our goal is to use cell
fusion-based technologies to transform the biomedical sciences by
helping to identify genetic factors contributing to numerous rare
diseases with unknown medical causes,” said Dr. Jung Joon Sung, CEO
of Curamys. “MaxCyte’s Platform will enable us to advance this
technology so we can expand our global reach and ultimately, help
more patients living with rare diseases.”
MaxCyte’s ExPERT™ instrument portfolio is the
next generation of leading, clinically-validated electroporation
technology for complex and scalable cell engineering. By delivering
high transfection efficiency, seamless scalability and enhanced
functionality, the ExPERT™ platform delivers the high-end
performance essential to enabling the next wave of biological and
cellular therapeutics. Curamys is MaxCyte’s 18th SPL overall, which
generate pre-commercial milestone revenue and the vast majority of
which include post-commercial revenue.
About MaxCyteMaxCyte is a
leading, cell-engineering focused company providing enabling
platform technologies to advance the discovery, development and
commercialization of next-generation cell therapeutics and to
support innovative, cell-based research. Over the past 20 years, we
have developed and commercialized our proprietary Flow
Electroporation® technology, which facilitates complex engineering
of a wide variety of cells. Our ExPERT™ platform, which is based on
our Flow Electroporation technology, has been designed to support
the rapidly expanding cell therapy market and can be utilized
across the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx™, STx™ GTx™ and VLx™;
a portfolio of proprietary related processing assemblies or
disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio. Learn more at
maxcyte.com and follow us on Twitter and LinkedIn.
About CuramysCuramys is a
biotechnology company that develops cell & gene therapeutics
intended to offer treatment for rare intractable diseases. The
company's platform uses cell fusion technology – a novel approach
that allows the healthiest and youngest cells to find apoptotic
(diseased or dying) cells and fuse together so the apoptotic cells
can heal. This technology can be combined with stem cell therapy to
develop a therapeutic agent, and it can be used for finding the
causes of intractable diseases at the cellular level enabling
healthcare professionals to treat certain rare genetic diseases.
Currently, Curamys is devoted to develop therapeutics for the
treatment of rare diseases, including Duchenne muscular dystrophy,
Lou Gehrig’s disease (i.e., amyotrophic lateral sclerosis), and
nonketotic hyperglycinemia. Learn more at curamys.com.
MaxCyte Contacts:
US IR AdviserGilmartin
GroupDavid Deuchler, CFA+1 415-937-5400jr@maxcyte.com
US Media RelationsSpectrum Seismic
CollaborativeValerie Enes+1
408-497-8568valerie@spectrumscience.com
Nominated Adviser and Joint Corporate
BrokerPanmure GordonEmma Earl / Freddy
CrossleyCorporate BrokingRupert Dearden+44 (0)20 7886 2500
UK IR AdviserConsilium Strategic
CommunicationsMary-Jane ElliottChris Welsh+44 (0)203 709
5700maxcyte@consilium-comms.com
Curamys Contact
David Lee, CDOdavid.lee@curamys.co.kr
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jul 2023 to Jul 2024